Abstract: The present invention relates to the use of a CD24 protein for preventing or treating relapse of a cancer in a subject. The present invention also relates to the use of a CD24 protein for reducing cancer stem cell activity.
Type:
Grant
Filed:
June 3, 2019
Date of Patent:
February 27, 2024
Assignees:
ONCOIMMUNE, INC., UNIVERSITY OF MARYLAND, BALTIMORE
Abstract: The present invention relates to the use of a CD24 protein for preventing or treating relapse of a cancer in a subject. The present invention also relates to the use of a CD24 protein for reducing cancer stem cell activity.
Type:
Application
Filed:
June 3, 2019
Publication date:
September 2, 2021
Applicants:
ONCOIMMUNE, INC, UNIVERSITY OF MARYLAND, BALTIMORE
Abstract: Provided herein are anti-CD24 antibodies that selectively bind human CD24 expressed in cancer cells, but not human CD24 expressed in non-cancerous cells, and the use of such antibodies in cancer therapy.
Type:
Application
Filed:
May 13, 2019
Publication date:
July 15, 2021
Applicants:
ONCOIMMUNE, INC, CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER
Inventors:
Yang Liu, Pan Zheng, Rhonda Flores, Hung-Yen Chou, Zhihong Xue, Peiying Ye, Martin Devenport
Abstract: The present invention relates to the use of a CD24 protein for lowering low-density lipoprotein cholesterol levels, treating and preventing atherosclerosis, and for reducing risk of cardiovascular disease.
Abstract: This invention relates to the use of a CD24 protein for treating leptin-deficient conditions, such as lipodystrophy, by increasing the level of circulating leptin.
Abstract: The present invention relates to a method of treating, mitigating, minimizing, or preventing HIV-1/AIDS by administering a CD24 protein to a subject in need thereof. Also provided herein is use of a CD24 protein in the manufacture of a medicament for treating HIV-1/AIDS. Further, provided is a pharmaceutical composition comprising a pharmaceutically acceptable amount of a CD24 protein.
Type:
Application
Filed:
March 5, 2019
Publication date:
February 18, 2021
Applicants:
ONCOIMMUNE, INC, UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, INSTITUTE OF BIOPHYSICS, CHINESE ACADEMY OF SCIENCES, KUNMING INSTITUTE OF ZOOLOGY, CHINESE ACADEMY OF SCIENCES
Inventors:
Yang Liu, Pan Zhang, Lishan Su, Yong-Tang Zheng, Liguo Zhang
Abstract: This invention relates to the use of a CD24 protein for treating leptin-deficient conditions, such as lipodystrophy, by increasing the level of circulating leptin.
Abstract: Provided herein is a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
Type:
Grant
Filed:
August 16, 2018
Date of Patent:
October 6, 2020
Assignee:
ONCOIMMUNE, INC.
Inventors:
Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng
Abstract: This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.
Abstract: The present invention relates to a CD24 protein for treating immune-related adverse events (irAEs) associated with cancer immunotherapy. Provided herein is a method of treating, mitigating, minimizing, or preventing immunerelated adverse events (irAEs) associated with a cancer immunotherapy by administering a CD24 protein to a subject in need thereof. The irAE may be diarrhea or another gastrointestinal disorder, pure red cell aplasia, microcytic anemia, lupus, autoimmune nephritism, autoimmune hepatitis, pneumonitis, myocarditis, pericarditis, endocrinopathy, Addison's disease, hypogonadism, Sjogren's syndrome, or type I diabetes. The CCD24 protein may comprise a mature human CD24 or a variant thereof.
Type:
Application
Filed:
May 21, 2018
Publication date:
June 25, 2020
Applicants:
ONCOIMMUNE, INC., CHILDREN'S NATIONAL MEDICAL CENTER
Abstract: The present invention relates to compositions and their use in methods of protecting and maintaining oligodendrocytes, and of treating demyelinating disorders
Type:
Application
Filed:
May 15, 2018
Publication date:
June 11, 2020
Applicants:
ONCOIMMUNE, INC., CHILDREN'S NATIONAL MEDICAL CENTER
Inventors:
Yang LIU, Pan ZHENG, Martin DEVENPORT, Ning LI
Abstract: This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.
Abstract: This invention relates to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. Specifically, the disclosure provides a CTLA-4 protein comprising a mutant extracellular domain of CTLA-4, wherein the CTLA-4 protein exhibits reduced binding to an anti-CTLA-4 antibody as compared to a wild-type extracellular domain of CTLA-4, wherein the anti-CTLA-4 antibody has anti-cancer immunotherapeutic activity.
Type:
Application
Filed:
September 19, 2017
Publication date:
August 29, 2019
Applicants:
ONCOIMMUNE, INC., CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER
Inventors:
Yang LIU, Pan ZHENG, Martin DEVENPORT, Wei WU, Xuexiang DU, Mingyue LIU, Fei TANG
Abstract: This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.
Abstract: This invention relates to the use of a CD24 protein for treating leptin-deficient conditions, such as lipodystrophy, by increasing the level of circulating leptin.
Abstract: The present invention relates to treating a hematologic cancer using a Hypoxia-Inducible Factor (HIF inhibitor). The invention also relates to inducing acute myeloid leukemia remission using the HIF inhibitor. The invention further relates to inhibiting a maintenance or survival function of a cancer stem cell (CSC) using the HIF inhibitor.
Type:
Grant
Filed:
March 3, 2017
Date of Patent:
January 30, 2018
Assignee:
ONCOIMMUNE, INC.
Inventors:
Yang Liu, Yin Wang, Yan Liu, Sami N. Malek, Pan Zheng
Abstract: Provided herein is a method of treating rheumatoid arthritis using a CD24 protein. The CD24 protein may include mature human or mouse CD24, as well as a N- or C-terminally fused portion of a mammalian immunoglobulin.
Type:
Application
Filed:
April 28, 2011
Publication date:
May 30, 2013
Applicant:
ONCOIMMUNE, INC.
Inventors:
Xincheng Zheng, Wei Wu, Yang Liu, Pan Zheng